Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from CellSource Co., Ltd. ( (JP:4880) ).
CellSource Co., Ltd. announced a leadership change, with Masayuki Yamakawa, a co-founder and medical doctor, taking over as Representative Director and CEO from Takashi Sawada. This transition aims to leverage the company’s robust management structure for significant expansion in regenerative medicine and self-funded healthcare, marking a shift to a more proactive management approach.
The most recent analyst rating on (JP:4880) stock is a Buy with a Yen1600.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.
More about CellSource Co., Ltd.
CellSource Co., Ltd. operates in the regenerative medicine and self-funded healthcare industry, focusing on expanding its corporate value through innovative medical solutions.
Average Trading Volume: 61,591
Technical Sentiment Signal: Sell
Current Market Cap: Yen14.58B
Find detailed analytics on 4880 stock on TipRanks’ Stock Analysis page.